195 related articles for article (PubMed ID: 29415846)
1. Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness.
Robertson AG; Easter MM; Lin HJ; Frisman LK; Swanson JW; Swartz MS
J Subst Abuse Treat; 2018 Mar; 86():17-25. PubMed ID: 29415846
[TBL] [Abstract][Full Text] [Related]
2. Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes.
Robertson AG; Easter MM; Lin H; Frisman LK; Swanson JW; Swartz MS
Am J Psychiatry; 2018 Jul; 175(7):665-673. PubMed ID: 29961358
[TBL] [Abstract][Full Text] [Related]
3. Gender-specific participation and outcomes among jail diversion clients with co-occurring substance use and mental health disorders.
Robertson AG; Easter MM; Lin HJ; Khoury D; Pierce J; Swanson J; Swartz M
J Subst Abuse Treat; 2020 Aug; 115():108035. PubMed ID: 32600621
[TBL] [Abstract][Full Text] [Related]
4. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
Bahji A; Carlone D; Altomare J
Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
[TBL] [Abstract][Full Text] [Related]
5. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
[TBL] [Abstract][Full Text] [Related]
6. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy for opioid addiction in community corrections.
Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
[TBL] [Abstract][Full Text] [Related]
8. Cost and utilization outcomes of opioid-dependence treatments.
Baser O; Chalk M; Fiellin DA; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
[TBL] [Abstract][Full Text] [Related]
9. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
[TBL] [Abstract][Full Text] [Related]
10. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
[TBL] [Abstract][Full Text] [Related]
12. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
[TBL] [Abstract][Full Text] [Related]
13. Co-occurring risk factors for arrest among persons with opioid abuse and dependence: implications for developing interventions to limit criminal justice involvement.
Fisher WH; Clark R; Baxter J; Barton B; O'Connell E; Aweh G
J Subst Abuse Treat; 2014 Sep; 47(3):197-201. PubMed ID: 25012550
[TBL] [Abstract][Full Text] [Related]
14. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
15. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.
Griffin ML; Dodd DR; Potter JS; Rice LS; Dickinson W; Sparenborg S; Weiss RD
Am J Drug Alcohol Abuse; 2014 Mar; 40(2):157-62. PubMed ID: 24219166
[TBL] [Abstract][Full Text] [Related]
16. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
Krawczyk N; Picher CE; Feder KA; Saloner B
Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
[TBL] [Abstract][Full Text] [Related]
17. The role of co-occurring disorders in criminal recidivism and psychiatric recovery among adults with opioid use disorder and criminal-legal involvement: A statewide retrospective cohort study.
Lawson SG; Foudray CMA; Lowder EM; Ray B; Carey KL
J Subst Use Addict Treat; 2024 Jan; 156():209192. PubMed ID: 37866440
[TBL] [Abstract][Full Text] [Related]
18. Patterns of justice involvement among adults with schizophrenia and bipolar disorder: key risk factors.
Robertson AG; Swanson JW; Frisman LK; Lin H; Swartz MS
Psychiatr Serv; 2014 Jul; 65(7):931-8. PubMed ID: 24633645
[TBL] [Abstract][Full Text] [Related]
19. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
McCann DJ
Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
[TBL] [Abstract][Full Text] [Related]
20. Costs of criminal justice involvement among persons with serious mental illness in connecticut.
Swanson JW; Frisman LK; Robertson AG; Lin HJ; Trestman RL; Shelton DA; Parr K; Rodis E; Buchanan A; Swartz MS
Psychiatr Serv; 2013 Jul; 64(7):630-7. PubMed ID: 23494058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
